Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
SAMDAILY.US - ISSUE OF OCTOBER 09, 2021 SAM #7252
MODIFICATION

A -- ATUM Evaluation License and Materials: Cell Line Development Expression Vector Optimization

Notice Date
10/7/2021 1:48:32 PM
 
Notice Type
Justification
 
NAICS
541714 — Research and Development in Biotechnology (except Nanobiotechnology)
 
Contracting Office
NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
 
ZIP Code
20892
 
Solicitation Number
75N93021P01384
 
Archive Date
11/07/2021
 
Point of Contact
Lu Chang, Phone: 2406273034
 
E-Mail Address
lu-chang.lu@nih.gov
(lu-chang.lu@nih.gov)
 
Award Number
75N93021P01384
 
Award Date
09/20/2021
 
Description
The National Institute of Allergy and Infectious Diseases (NIAID)�s Vaccine Research Center (VRC) has a Vaccine Production Program (VPP) with a Cell Line Development team that is responsible for generating specific clonally-derived cell lines expressing monoclonal antibodies and vaccine candidates that will be used for manufacturing material that is acceptable for use in human clinical trials. This process begins with transfection of a mammalian cell line with plasmid DNA encoding the protein of interest. DNA TwoPointO, Inc., d/b/a ATUM (�ATUM�) has expression vectors that are based on unique proprietary technology, synthetic transposons. ATUM�s unique technology provides the only commercially available transposon-based system, which is a specific way of integrating the genes into the host cell line that uniquely meets the requirements of our project. This specific technology results in higher-producing clones than the random integration system that the VPP currently uses. More importantly, this transposon-based technology results in faster and more reproducible pool and clone generation, which would potentially allow the VPP to move projects forward much more quickly. Other alternative methods for exogenous gene expression are vulnerable to truncation, deletion, scrambling, and other problems that can occur during the random integration processes that are commonly used in cell line development. ATUM�s transposon based process is able to avoid these issues and the selection process is therefore accelerated; creating higher-producing clones at a consistent product quality, which will save significant time and money. Reference attached Limited Source Justification.�
 
Web Link
SAM.gov Permalink
(https://beta.sam.gov/opp/e8a0f383bcd8425bae66695dc95e88db/view)
 
Place of Performance
Address: Newark, CA 94560, USA
Zip Code: 94560
Country: USA
 
Record
SN06153251-F 20211009/211007230115 (samdaily.us)
 
Source
SAM.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.